Cognitive evolution in natalizumab-treated multiple sclerosis patients
Background Cognitive dysfunction affects up to 65% of multiple sclerosis (MS) patients and progresses over time. Natalizumab has been shown to be superior to placebo in preserving cognition for the first two years of therapy. Objectives The objectives of this study are to understand the impact of na...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publishing
2016-06-01
|
| Saila: | Multiple Sclerosis Journal - Experimental, Translational and Clinical |
| Sarrera elektronikoa: | https://doi.org/10.1177/2055217316657116 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|